meta|Evidence - COVID-19
click on circles to display study description...
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=-9) vs. Comirnaty (tozinameran - Pfizer/BIONTECH) (n=-9)
randomized controlled trial risk of bias NA
eight groups receiving ChAd/ChAd, ChAd/BNT, BNT/BNT or BNT/ChAd, administered at 28- or 84-day intervals
8 arms
COVID-19 prophylaxis (excluding children)
single-blind
UK
non-inferiority tria
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=12282) vs. control (n=11962)
randomized controlled trial risk of bias NA
ChAdOx1 nCoV-19 vaccin
as a single-dose or two-dose regimen (28 days apart) at either the low dose ( 2·2 × 10¹⁰ virus particles) or the standard dose (3·5–6·5 × 10¹⁰ virus particles)
quadrivalent MenACWY protein-polysaccharide conjugate vaccine.
ten different groups
COVID-19 prophylaxis (excluding children)
We recruited participants in an age-escalation manner. We recruited adults aged 18 –55 years, then adults aged 56–69 years, and then adults aged 70 years and older
single-blind
20 centres in the UK
Safety was assessed in all participants who received at least one dose
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=5807) vs. control (n=5829)
randomized controlled trial some concerns about risk of bias
ChAdOx1 nCoV-19 vaccine
ChAdOx1nCoV-19 group received two doses containing 5 × 10¹⁰ viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort)
meningococcal group A, C, W, and Y conjugate vaccine or saline
interval between dose 1 and dose 2 ranged from 4 to 26 weeks
COVID-19 prophylaxis (excluding children)
exclusion criteria: h history of anaphylaxis or angioedema; participants with severe and/or uncontrolled cardiovascular, gastrointestinal, liver, renal, endocrine/metabolic disease, and neurological illnesses; as well as those with immunosuppression
double blind
UK, Brazil, and South Africa.
pooled analysis of 4 studies done across the UK, Brazil, and South Africa : ISRCTN89951424(COV003), NCT04400838 (COV002), NCT04324606 (COV001), and NCT04444674 (COV005).
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=21583) vs. placebo (n=10796)
randomized controlled trial risk of bias NA
AZD1222
two doses of 5 x1010 viral particles four weeks apart
placebo
COVID-19 prophylaxis (excluding children)
double-blind
88 sites in the United States, Chile and Peru
Unsolicited adverse events were recorded for all participants for 28 days after each dose
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=-9) vs. placebo (n=10796)
randomized controlled trial risk of bias NA
AZD1222
two doses of 5 x1010 viral particles four weeks apart
placebo
COVID-19 prophylaxis (excluding children)
double-blind
88 sites in the United States, Chile and Peru
Unsolicited adverse events were recorded for all participants for 28 days after each dose
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=174) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
AZD1222 (ChAdOx1 nCoV-19) Days 1 and 29
placebo
COVID-19 prophylaxis (excluding children)
double-blind
5 centers, Japan
Unsolicited AEs were recorded for 28 days following each dose (Days 1–29 and Days 29–57
phase 1-2
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=-9) vs. vaccines (n=-9)
randomized controlled trial risk of bias NA
D2 vaxzevria
all other D2 vaccines
6 arms : D1 Vaxzevria D2 Vaxzevria or Spikevax or NovavaxD1 Comirnaty D2 Comirnaty or Spikevax or Novavax
COVID-19 prophylaxis (excluding children)
single-blind
UK multicentre
non-inferiority trial
powered by vis.js Network